Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer’s Treatment
August 29, 2018 at 04:00 AM EDT
Source: Streetwise Reports 08/29/2018 The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development. ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB), a biotechnology company focused on the [...]
